Mechanistically, FOXA2 overexpression enhanced the inhibitory effect of lenvatinib on HCC cells by up-regulating the AMPK-mTOR pathway and promoting autophagy in lenvatinib-treated HCC cells [134]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.